Jump to content
RemedySpot.com

Biosimilar Rituxan announced

Rate this topic


Guest guest

Recommended Posts

Spectrum Pharmaceuticals Inc. said it will develop a biosimilar version of the

cancer drug Rituxan through a new partnership with Viropro Inc.

Spectrum makes Zevalin, a CD20 targeted radiotherapy monoclonal sometimes

used in CLL.

Other versions of rituxan are expected from India and other countries.

Source: Bloomberg

~chris

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...